The third webinar of Cytel's Comparative Effectiveness series.

Led by Bart Heeg, Gabriel Tremblay, and Emma Mackay, this webinar will delve into Flexible time-to-event NMAs and their consequences. The experts will highlight the significance of Bayesian hierarchical TTE NMA in overcoming immature pivotal trial data.

During the session, Emma will present a case study that focuses on Bayesian hierarchical TTE NMAs for tumor agnostic trials. Gabriel will also discuss the application of theses from a HTA modelling acceptance perspective.

Join us for this informative session and gain valuable insights into the importance of Flexible time-to-event NMAs and the Bayesian hierarchical TTE NMA.

Meet the Speakers: 

• Bart Heeg, Vice President HEOR Global, Cytel
• Gabriel Tremblay, Vice President, Advanced Analytics
• Emma Mackay, Research Principal, Statistics